ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
Shruthi Padavu1, Ballamoole Krishna Kumar1, Anoop Kumar2 and Praveen Rai1
1Nitte (Deemed to be University), Nitte University Centre for Science Education and Research (NUCSER), Division of Infectious Diseases, Deralakatte, Mangaluru, Karnataka, India.
2National Institute of Biologicals (NIB), Ministry of Health & Family Welfare, Government of India A-32, Sector-62, Noida, India.
Article Number: 8109 | © The Author(s). 2023
J Pure Appl Microbiol. 2023;17(1):554-566. https://doi.org/10.22207/JPAM.17.1.53
Received: 17 September 2022 | Accepted: 17 January 2023 | Published online: 03 March 2023
Issue online: March 2023
Abstract

Globally, cervical cancer is the fourth most common cancer among women. After being cloned from a recurring cervical lesion in 1987, Human papillomavirus (HPV) type-45 was identified as a high-risk HPV type. It is the third most common cancer-causing HPV subtype, after HPV-16 and HPV-18. Immunogenic epitopes and structural features provide the most useful information for vaccine development. Computational algorithms provide quick, simple, trustworthy, and cost-efficient methods for predicting immunogenic epitopes. In this study, both B and T cell epitopes have been identified as potential immunogens that can elicit a response from the host system. Three potential B-cell epitopes, i.e., SIAGQYRGQCNTCCDQ, LQEIVLHLEPQNELDP, and DSTVYLPPPSVARVVS, were identified in this study. A potential epitope for E6 (ATLERTEVY) was predicted to 8 MHC-I alleles (HLA-A*30:02, HLA-B*15:01, HLA-A*01:01, HLA-A*26:01, HLA-A*32:01, HLA-B*35:01, HLA-B*58:01, HLA-A*11:01) and for L1 epitope (NVFPIFLQM) was predicted for 4 MHC-I alleles (HLA-A*30:02, HLA-A*32:01, HLA-B*53:01, HLA-B*51:01). To conclude, the epitopes identified here might potentially be useful for developing a cervical cancer vaccine against HPV-45 strains, but in vitro and in vivo trials are needed to validate their safety and efficacy.

Keywords

Human Papillomavirus, Cervical Cancer, Immunogenic Epitopes, Vaccine, In silico

Article Metrics

Article View: 904

Share This Article

© The Author(s) 2023. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.